[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388605":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":20,"responsibleParty":33,"collaborators":35,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":7,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":7,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":23,"whyStopped":7,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Melvin Chua, MD","PRINCIPAL_INVESTIGATOR",[13,16],{"name":10,"role":14,"phone":7,"phoneExt":7,"email":15},"CONTACT","melvin.chua.l.k@singhealth.com.sg",{"name":17,"role":14,"phone":18,"phoneExt":7,"email":19},"Enya Ong","+65 6436 8000","enya.ong.h.w@nccs.com.sg",[21],{"facility":22,"status":23,"city":24,"state":7,"zip":25,"country":24,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":7},"National Cancer Center Singapore","RECRUITING","Singapore","169690","SG",{"type":28,"coordinates":29},"Point",[30,31],103.85007,1.28967,{"lat":31,"lon":30},{"type":34,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[36,39,41,44,46],{"name":37,"class":38},"National Medical Research Council (NMRC), Singapore","OTHER_GOV",{"name":40,"class":6},"Duke-NUS Graduate Medical School",{"name":42,"class":43},"Ferring Pharmaceuticals","INDUSTRY",{"name":45,"class":43},"ImmunoSCAPE",{"name":47,"class":48},"Decipher Biosciences","UNKNOWN","100388605","discovery-of-biomarkers-for-intrinsic-radiation-sensitivity-in-cancer-patients-100388605",false,"NCT04340024","Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients","Inclusion Criteria:\n\n* Patients with severe side effects from radiotherapy\n* Patients with a type of cancer that is associated with sensitivity to radiotherapy\n\nExclusion Criteria:\n\n* Age of patient must be between 21 (inclusive) and 99 (exclusive)","ALL","21 Years","99 Years",{"count":59,"type":60},5000,"ESTIMATED","OBSERVATIONAL","Patients with cancers that are sensitive to radiotherapy treatment and\u002For patients who have experienced severe acute\u002F late side effects to radiotherapy will be recruited to the study. Blood and\u002For matched tumour-normal tissue pairs will be collected. Blood and\u002For tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.",[64,65,66],"Nasopharyngeal Cancer","Prostate Cancer","Other Cancer",[68,69,70,71,72],"Radiotherapy","Biomarkers","Genomics","Immunomics","Precision medicine","2025-06-10",{"date":75,"type":76},"2025-06-11","ACTUAL",{"date":78,"type":76},"2015-09-30",{"date":80,"type":60},"2026-12-31",{"name":5,"class":6},1]